Author: admin

From Service to Streetwear: How a Veteran and His Wife Built CDR Clothing Into an Empowerment-Driven Urban Fashion Brand

“”My wife and I started this brand because we truly believe God gave us a vision to bring people together. We have seen what commitment, determination, and resilience can do in our own lives, and we want every person who wears CDR to feel that same fire inside them. This is bigger than clothing. This is about community and belief.” – Spokesperson”
CDR Clothing is redefining what it means to wear your values. Founded by a veteran and his wife, the brand fuses urban streetwear with a mission of empowerment, encouraging customers to stay committed, determined, and resilient in every area of life. With new product launches including everyday hoodies and upcoming women’s activewear, CDR is expanding its reach.

Behind every great brand there is a story worth telling. For CDR Clothing, that story begins with service, faith, and an unshakable belief in the power of positive affirmations. Founded by a veteran and his wife, CDR Clothing has emerged as a distinctive voice in the urban fashion landscape, offering stylish apparel that carries a deeper purpose.

The name CDR is an acronym that captures the brand’s philosophy. Committed, Determined, and Resilient. These three words are not just a tagline. They are principles that the founders live by every day, principles forged through military service and strengthened through the journey of building a business together as a married couple. Their partnership brings a unique dynamic to the brand, blending discipline with creativity and strategy with heart.

The couple has been open about the role faith plays in their entrepreneurial journey. They describe the vision for CDR Clothing as something God placed on their hearts, a calling to use fashion as a vehicle for encouragement. In a marketplace often driven by trends and hype, CDR Clothing stands apart by anchoring its identity in something lasting. The brand exists to inspire people to chase their dreams regardless of obstacles and to remind them that they already possess the qualities needed to succeed.

This week marks an exciting milestone for the brand with the release of the Everyday Hoodies collection. Designed for men and women who appreciate urban fashion and carry a belief in their own potential, the new hoodies blend comfort, style, and meaning. They are intended to be versatile pieces that fit into any lifestyle, whether the wearer is heading to work, meeting friends, or simply running errands around town. The design approach reflects the brand’s understanding that empowerment should be accessible and wearable, not reserved for special occasions.

The timing of this launch also signals broader ambitions for CDR Clothing. The brand has confirmed that a women’s yoga and workout wear line is in development and set to arrive soon. This move into activewear demonstrates that CDR is listening to its community and expanding to serve customers across different aspects of their lives. The activewear line will carry the same motivational DNA that runs through every CDR product, giving women a way to bring the brand’s empowering message into their fitness routines and wellness practices.

CDR Clothing’s appeal lies in its authenticity. The founders are not simply marketing positivity from a distance. They are living proof of what commitment, determination, and resilience can produce. Building a clothing brand from the ground up as a husband and wife team requires every ounce of those qualities, and their personal experience lends credibility to the message they share. Customers are not just buying a product. They are joining a community of like-minded individuals who believe in lifting each other up.

The brand’s social media presence reflects this community-first approach. Through platforms like Instagram, TikTok, and Facebook, CDR Clothing shares motivational content, product updates, and glimpses into the daily life of the brand. The engagement from followers continues to grow as more people discover a clothing line that speaks to their aspirations and values.

Urban fashion has always been about identity and expression. CDR Clothing takes that tradition and elevates it by embedding encouragement into every stitch. As the brand continues to grow and release new collections, its core message remains the same. No matter what your goals may be, to achieve them you will have to be committed, determined, and resilient. CDR Clothing is here to help you wear that truth proudly.

CONTACT: https://cdrclothing.com

https://www.instagram.com/cdrofficialclothing?igsh=MzllYzNydThuNW80

https://www.tiktok.com/@cdrofficialclothing?_r=1&_t=ZT-96sLmmWu6HN

https://www.facebook.com/share/1CJoPiv9Qt/?mibextid=wwXIfr

Media Contact
Company Name: CDR CLOTHING
Contact Person: Charles A. Ramsey II
Email: Send Email
Country: United States
Website: https://cdrclothing.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: From Service to Streetwear: How a Veteran and His Wife Built CDR Clothing Into an Empowerment-Driven Urban Fashion Brand

From Texture to Tone: Why Microneedling is the Secret Weapon for Post-Summer Skin Rehabilitation

From Texture to Tone: Why Microneedling is the Secret Weapon for Post-Summer Skin Rehabilitation

Every autumn we see patients carrying the effects of a summer spent outdoors, and many hope the damage will fade on its own,” a clinic spokesperson said. “It rarely does without intervention because sun-damaged cells do not shed at the rate healthy skin does. Microneedling gives the skin the stimulus it needs to clear damaged tissue and start producing quality new cells. The results after a proper course in the cooler months are some of the most satisfying we deliver all year.
Define Clinic in Beaconsfield is seeing growing demand for autumn microneedling treatments to address sun damage after summer exposure. Led by Dr Benji Dhillon, the clinic uses microneedling to stimulate collagen production and support skin resurfacing, helping improve uneven tone, discolouration and rough texture. Patients starting treatment in early autumn often see clearer, more even skin by spring.

Define Clinic is an aesthetic and dermatology practice in Beaconsfield serving patients across Buckinghamshire and the surrounding area. Dr Benji Dhillon leads the clinical team and oversees a treatment portfolio built around evidence-based care at every stage of a patient’s skin journey. As the summer season ends, the clinic sees a consistent increase in patients seeking treatment for the skin changes left by sun exposure. Autumn and winter represent a clinically sound window for addressing those changes before the following year’s UV season begins.

The months following prolonged sun exposure are when the skin’s surface tells the full story of the summer it has just been through. Uneven tone, patches of discolouration, rough texture and the flat dullness that settles into sun-damaged skin are all signs that the skin needs more than a change in skincare routine. Microneedling repairs sun damage. Define Clinic addresses those changes by triggering the skin’s own repair response and accelerating the turnover of damaged surface cells. The treatment creates thousands of controlled micro-channels in the skin that prompt fresh collagen production and push the skin’s natural resurfacing process forward at a pace it would never reach on its own.

“Every autumn we see patients come in carrying the consequences of a summer spent outdoors, and most of them have been hoping the damage would fade on its own,” a clinic spokesperson said. “It rarely does without intervention because sun-damaged cells do not simply shed at the rate that healthy skin does. Microneedling gives the skin the stimulus it needs to clear that backlog of damaged tissue and start producing quality new cells in its place. The results patients see after a proper course in the cooler months are some of the most satisfying we deliver all year.”

Sun damage repair is most effective when it is started early in the autumn rather than left until the skin has had months to settle into its post-summer state. Patients who begin a microneedling course in September or October tend to see the clearest improvement by the following spring. Skin resurfacing through a structured course of treatment produces a cumulative result that builds with each session and continues to improve for weeks after the final appointment. Patients who complete a full course consistently report clarity and evenness in their skin that topical products alone have never been able to provide.

About Define Clinic

Define Clinic is a specialist aesthetic and dermatology practice in Beaconsfield serving patients across Buckinghamshire and the surrounding area. The clinic offers skin resurfacing, microneedling, dermal fillers, anti-wrinkle injections and advanced dermatology services for patients at every stage of their skin journey. The practice is led by Dr Benji Dhillon, who focuses on evidence-based care and natural-looking outcomes for every patient seen at the clinic.

Media Contact
Company Name: Define Clinic
Email: Send Email
Phone: 01494 932700, 0203 336 4100
Address:9, 10 Windmill St
City: London
Country: United Kingdom
Website: https://defineclinic.com

Gastroparesis Market Shows Strong Future Potential with Increasing Industry Investments by 2036 – DelveInsight | Vanda Pharma, Dr. Falk Pharma GmbH, Alfasigma S.p.A., PTC Therapeutics, CinDome Pharma

The Key Gastroparesis Companies CinDome Pharma, Inc., Evoke Pharma, Vanda Pharmaceuticals, Ironwood Pharmaceuticals, Takeda, Neurogastrx, Inc, PTC Therapeutics, Theravance Biopharma, Chugai Pharma, GlaxoSmithKline, Processa Pharmaceuticals, and others.

 

DelveInsight’s “Gastroparesis Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Gastroparesis, historical and forecasted epidemiology as well as the Gastroparesis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

Get a Free sample for the Gastroparesis Market Report:

https://www.delveinsight.com/report-store/gastroparesis-market

 

Some of the key facts of the Gastroparesis Market Report:

  • The Gastroparesis market size was valued at approximately USD 150 million in 2025 and is expected to reach nearly USD 970 million by 2036, expanding at a CAGR of 18% during the forecast period from 2026 to 2036.

  • In April 2026, Dr. Falk Pharma GmbH and Renexxion Ireland announced that data from the Global Phase IIb (MOVE-IT) study of naronapride in 328 adults with moderate-to-severe idiopathic or diabetic gastroparesis had been selected for a late-breaking oral presentation at DDW 2026 in the US.

  • In March 2026, CinDome Pharma announced the completion of patient enrollment in its Phase 2 envisionGI trial evaluating deudomperidone (CIN-102) for adults with idiopathic gastroparesis. Deudomperidone, a novel chemical entity, is being developed to alleviate symptoms of gastroparesis, a condition affecting an estimated 16 million people in the United States and currently lacking FDA-approved long-term treatment options. Topline safety and efficacy results from the envisionGI study are anticipated in the second half of 2026.

  • In September 2025, CinDome Pharma, a CinRx portfolio company focused on developing safe, long-term treatments for gastroparesis, announced the completion of enrollment in the envision3D Phase 2 trial of deudomperidone for adults with diabetic gastroparesis. Topline safety and efficacy data are expected in Q1 2026.

  • In June 2025, CinDome Pharma announced that the first participant had been dosed in the ENVISION GI Phase II clinical trial of CIN-102 in adults with idiopathic gastroparesis. Based on a strong safety signal and notable reductions in nausea and vomiting symptoms observed in a blinded interim analysis of the ongoing Phase II Envision3D study in patients with diabetic gastroparesis, CinDome has raised an additional USD 40 million of new capital to initiate this Phase II trial to investigate deudomperidone as a treatment for a broader population of patients with this chronic disease.

  • In May 2025, Renexxion Ireland, in collaboration with its partner Dr. Falk Pharma GmbH, announced the successful completion of patient enrollment for the global Phase IIb MOVE-IT study evaluating the safety and efficacy of naronapride for the treatment of gastroparesis. The MOVE-IT study achieved its target enrolment of 320 patients.

  • In January 2025, Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) provided an update on tradipitant’s development, confirming that it has accepted the FDA’s offer for a hearing on the New Drug Application for the treatment of gastroparesis.

  • Among the 7MM, the US represented the largest gastroparesis market, valued at approximately USD ~150 million in 2025, and is projected to grow at a significant CAGR through 2036.

  • Currently, the majorly prescribed class of therapies is prokinetics, such as oral or IV metoclopramide antiemetics and neuromodulators to manage symptoms.

  • Among the 7MM, the US accounted for the highest number of diagnosed prevalent cases of gastroparesis with ~724,000 cases in 2025.

  • In the US in 2025, the highest age-specific cases were seen in the 65+ age group, followed by those aged 48–57, while the lowest were in the 18–27 age group.

  • Gastroparesis as a disease predominantly affects women, with ~70% of the diagnosed patients being females, while only ~30% of the diagnosed patients are males.

  • Among etiology-specific cases across the 7MM, diabetes has the highest prevalence, followed by postsurgical causes, drug-induced cases, and then idiopathic cases.

  • Key Gastroparesis Companies: CinDome Pharma, Inc., Evoke Pharma, Vanda Pharmaceuticals, Ironwood Pharmaceuticals, Takeda, Neurogastrx, Inc, PTC Therapeutics, Theravance Biopharma, Chugai Pharma, GlaxoSmithKline, Processa Pharmaceuticals, and others

  • Key Gastroparesis Therapies: CIN-102, Metoclopramide Nasal Spray, Tradipitant, IW-9179, TAK-954, NG101, CNSA-001, velusetrag, GM-611, Camicinal, PCS12852, and others

  • The Gastroparesis epidemiology based on gender analyzed that Gastroparesis cases were higher in females in comparison to males, in all the 7MM countries

  • The Gastroparesis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gastroparesis pipeline products will significantly revolutionize the Gastroparesis market dynamics.

 

Gastroparesis Overview

Gastroparesis is a medical condition characterized by delayed emptying of the stomach contents into the small intestine, without the presence of any mechanical obstruction. This delay in gastric emptying can lead to symptoms such as nausea, vomiting, bloating, early satiety (feeling full quickly after eating), abdominal pain, and a lack of appetite.

 

To Know in detail about the Gastroparesis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Gastroparesis Market Forecast

 

Gastroparesis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Gastroparesis Epidemiology Segmentation:

The Gastroparesis market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

  • Total Diagnosed Prevalent Cases of Gastroparesis

  • Etiology-specific Cases of Gastroparesis

  • Gender-specific Diagnosed Prevalent Cases of Gastroparesis

  • Age-specific Diagnosed Prevalent Cases of Gastroparesis

  • Total Cases of Gastroparesis by the Severity of Delayed Gastric Emptying

  • Treated cases of Gastroparesis

 

Download the report to understand which factors are driving Gastroparesis epidemiology trends @ Gastroparesis Epidemiology Forecast

 

Gastroparesis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gastroparesis market or expected to get launched during the study period. The analysis covers Gastroparesis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Gastroparesis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Gastroparesis Therapies and Key Companies

  • Naronapride (ATI-7505): Renexxion

  • CIN-102 (deudomperidone): CinDome Pharma

  • NG101 (metopimazine): Neurogastrx

  • PCS12852: Processa Pharma/Intact Therapeutics

  • Metoclopramide Nasal Spray: Evoke Pharma

  • Tradipitant: Vanda Pharmaceuticals

  • IW-9179: Ironwood Pharmaceuticals

  • TAK-954: Takeda

  • NG101: Neurogastrx, Inc

  • CNSA-001: PTC Therapeutics

  • velusetrag: Theravance Biopharma

  • GM-611: Chugai Pharma

  • Camicinal: GlaxoSmithKline

  • PCS12852: Processa Pharmaceuticals

 

Discover more about therapies set to grab major Gastroparesis market share @ Gastroparesis Treatment Market

 

Gastroparesis Market Drivers

  • Rising prevalence of diabetes mellitus, a major risk factor for gastroparesis, is increasing the patient population requiring treatment.

  • Growing awareness and improved diagnostic techniques, including gastric emptying studies and advanced imaging methods, are supporting earlier diagnosis.

  • Significant unmet medical need and limited effective treatment options are driving demand for novel therapeutics.

  • A strong pipeline of emerging prokinetic agents and innovative therapies is expected to expand the treatment landscape and fuel market growth.

 

Gastroparesis Market Barriers

  • Limited availability of approved therapies with long-term efficacy and safety data remains a major challenge in disease management.

  • Complex and heterogeneous disease presentation can complicate diagnosis, treatment selection, and clinical trial design.

  • Potential side effects associated with existing prokinetic medications may limit their long-term use and patient adherence.

  • Lack of standardized treatment guidelines and variability in clinical practice can affect treatment outcomes.

 

Scope of the Gastroparesis Market Report

  • Study Period: 2022–2036

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Gastroparesis Companies: CinDome Pharma, Inc., Evoke Pharma, Vanda Pharmaceuticals, Ironwood Pharmaceuticals, Takeda, Neurogastrx, Inc, PTC Therapeutics, Theravance Biopharma, Chugai Pharma, GlaxoSmithKline, Processa Pharmaceuticals, and others

  • Key Gastroparesis Therapies: CIN-102, Metoclopramide Nasal Spray, Tradipitant, IW-9179, TAK-954, NG101, CNSA-001, velusetrag, GM-611, Camicinal, PCS12852, and others

  • Gastroparesis Therapeutic Assessment: Gastroparesis current marketed and Gastroparesis emerging therapies

  • Gastroparesis Market Dynamics: Gastroparesis market drivers and Gastroparesis market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Gastroparesis Unmet Needs, KOL’s views, Analyst’s views, Gastroparesis Market Access and Reimbursement

 

To know more about Gastroparesis companies working in the treatment market, visit @ Gastroparesis Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Gastroparesis Market Report Introduction

2. Executive Summary for Gastroparesis

3. SWOT analysis of Gastroparesis

4. Gastroparesis Patient Share (%) Overview at a Glance

5. Gastroparesis Market Overview at a Glance

6. Gastroparesis Disease Background and Overview

7. Gastroparesis Epidemiology and Patient Population

8. Country-Specific Patient Population of Gastroparesis

9. Gastroparesis Current Treatment and Medical Practices

10. Gastroparesis Unmet Needs

11. Gastroparesis Emerging Therapies

12. Gastroparesis Market Outlook

13. Country-Wise Gastroparesis Market Analysis (2022–2036)

14. Gastroparesis Market Access and Reimbursement of Therapies

15. Gastroparesis Market Drivers

16. Gastroparesis Market Barriers

17. Gastroparesis Appendix

18. Gastroparesis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gastroparesis Market Shows Strong Future Potential with Increasing Industry Investments by 2036 – DelveInsight | Vanda Pharma, Dr. Falk Pharma GmbH, Alfasigma S.p.A., PTC Therapeutics, CinDome Pharma

Focal Segmental Glomerulosclerosis Market Set for Strong Expansion Through 2036 Amid Rising Investment Interest – DelveInsight | Retrophin, AbbVie, AstraZeneca, Pfizer, Sanofi, Teva Pharma

The Key Focal Segmental Glomerulosclerosis Companies in the market include – Evergreen Therapeutics, Certa Therapeutics, River 3 Renal Corp, Boehringer Ingelheim, Dimerix Bioscience, Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, GlaxoSmithKline, Dimerix Bioscience Pty Ltd, ChemoCentryx, AstraZeneca, Genentech, Inc., Sanofi, Mallinckrodt ARD LLC, ACELYRIN Inc., Kyowa Kirin Co., Ltd., Bristol-Myers Squibb, and others.

 

DelveInsight’s “Focal Segmental Glomerulosclerosis Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Focal Segmental Glomerulosclerosis, historical and forecasted epidemiology as well as the Focal Segmental Glomerulosclerosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Get a Free sample for the Focal Segmental Glomerulosclerosis Market Report:

https://www.delveinsight.com/report-store/focal-segmental-glomerulosclerosis-fsgs-market

 

Some of the key facts of the Focal Segmental Glomerulosclerosis Market Report:

  • The Focal Segmental Glomerulosclerosis market size was valued approximately USD 734 Million in 2022 and is anticipated to grow with a significant CAGR during the study period (2022-2036).

  • In January 2026, The U.S. FDA has extended the review timeline for the supplemental New Drug Application (sNDA) of sparsentan (Filspari) for focal segmental glomerulosclerosis (FSGS). Travere Therapeutics, Inc. confirmed that the Prescription Drug User Fee Act (PDUFA) target action date has been moved from January 13, 2026, to April 13, 2026. No additional requests regarding the drug’s safety or manufacturing have been made.

  • In January 2026, Akebia Therapeutics announced that the first patient has been dosed in a Phase II clinical trial of praliciguat for the treatment of biopsy-confirmed FSGS.

  • In December 2025, Dimerix announced that it had received feedback from the US FDA on the clinical appropriateness of proteinuria reduction as an endpoint for full approval of DMX-200 in the ACTION3 Phase III trial in patients with FSGS. Dimerix plans to submit the requested information to the FDA ahead of the blinded statistical powering analysis and required ACTION3 protocol updates, with the analysis now expected in early 2026.

  • In September 2025, Travere Therapeutics, Inc. (Nasdaq: TVTX) announced that the U.S. Food and Drug Administration (FDA) has notified the company that, after additional evaluation of the supplemental New Drug Application (sNDA) for FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS), an advisory committee meeting will no longer be required. The sNDA continues under FDA review, with a Prescription Drug User Fee Act (PDUFA) target action date set for January 13, 2026.

  • In June 2025, The DUPLEX trial (NCT03493685) demonstrated that sparsentan, a dual endothelin-angiotensin receptor antagonist, resulted in a sustained reduction in proteinuria among patients with focal segmental glomerulosclerosis (FSGS).

  • In May 2025, Travere Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for FILSPARI (sparsentan), seeking full approval for the treatment of focal segmental glomerulosclerosis (FSGS).

  • In April 2025, Dimerix Limited and Amicus Therapeutics announced an exclusive licensing agreement granting Amicus the rights to commercialize Dimerix’s Phase III drug candidate, DMX-200, in the U.S. for all indications, including FSGS. Dimerix will maintain commercialization rights for DMX-200 in all regions outside the U.S.

  • In March 2025, Travere Therapeutics, Inc. announced that it will present three abstracts, including a late-breaking oral presentation, at the 2025 National Kidney Foundation (NKF) Spring Clinical Meetings, scheduled for April 10–13 in Boston, MA. The late-breaking session will showcase new analyses from the Phase III DUPLEX Study of FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS), highlighting that partial and complete proteinuria remission occurred earlier and more frequently with FILSPARI compared to irbesartan. The data also indicated that patients achieving proteinuria remission experienced low rates of kidney failure

  • In 2022, the US accounted for approximately 34% of the total FSGS market, with projections indicating a significant compound annual growth rate (CAGR) during the study period.

  • In 2022, the EU4 countries and the UK generated an estimated USD 147 million, with this figure expected to grow at a significant CAGR. Among the European nations, France held the largest market share in 2022, followed by Germany.

  • According to DelveInsight’s assessments, there were roughly 55 million diagnosed prevalent cases of FSGS in the 7MM in 2022, with expectations of a rise during the forecast period.

  • In 2022, around 26 million individuals in the United States were diagnosed with FSGS, and this number is projected to rise at an estimated CAGR throughout the study period from 2022 to 2036.

  • In EU4 and the UK, Germany had the largest diagnosed prevalent population of FSGS in 2022, with approximately 5 million cases, followed by France and Italy. Conversely, Spain had the lowest diagnosed prevalent population in EU4 and the UK in 2022.

  • Key Focal Segmental Glomerulosclerosis Companies: Evergreen Therapeutics, Certa Therapeutics, River 3 Renal Corp, Boehringer Ingelheim, Dimerix Bioscience, Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, GlaxoSmithKline, Dimerix Bioscience Pty Ltd, ChemoCentryx, AstraZeneca, Genentech, Inc., Sanofi, Mallinckrodt ARD LLC, ACELYRIN Inc., Kyowa Kirin Co., Ltd., Bristol-Myers Squibb, and others

  • Key Focal Segmental Glomerulosclerosis Therapies: EG-102, OCX-063, R3R 01, BI764198, DMX-200, GFB-887, VX-147, Losmapimod, Propagermanium, RE-021 (Sparsentan), CCX140-B, Dapagliflozin, rituximab, fresolimumab, Acthar Gel, VB119, Bleselumab, Abatacept, and others

  • The Focal Segmental Glomerulosclerosis epidemiology based on gender analyzed that Focal Segmental Glomerulosclerosis is more prevalent in males than females in the United States

  • The Focal Segmental Glomerulosclerosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Focal Segmental Glomerulosclerosis pipeline products will significantly revolutionize the Focal Segmental Glomerulosclerosis market dynamics.

 

Focal Segmental Glomerulosclerosis Overview

Focal Segmental Glomerulosclerosis (FSGS) is a rare kidney disorder characterized by scarring (sclerosis) of some of the kidney’s glomeruli, which are the small filtering units. This scarring can lead to protein leakage into the urine, kidney dysfunction, and eventually kidney failure if untreated. FSGS can be primary (idiopathic) or secondary, caused by other conditions like infections, obesity, or genetic factors. Symptoms may include swelling, high blood pressure, and foamy urine. Treatment typically involves managing symptoms and preventing further kidney damage.

 

To Know in detail about the Focal Segmental Glomerulosclerosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Focal Segmental Glomerulosclerosis Market Forecast

 

Focal Segmental Glomerulosclerosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Focal Segmental Glomerulosclerosis Epidemiology Segmentation:

The Focal Segmental Glomerulosclerosis market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

  • Total Prevalence of Focal Segmental Glomerulosclerosis

  • Prevalent Cases of Focal Segmental Glomerulosclerosis by severity

  • Gender-specific Prevalence of Focal Segmental Glomerulosclerosis

  • Diagnosed Cases of Episodic and Chronic Focal Segmental Glomerulosclerosis

 

Download the report to understand which factors are driving Focal Segmental Glomerulosclerosis epidemiology trends @ Focal Segmental Glomerulosclerosis Epidemiology Forecast

 

Focal Segmental Glomerulosclerosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Focal Segmental Glomerulosclerosis market or expected to get launched during the study period. The analysis covers Focal Segmental Glomerulosclerosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Focal Segmental Glomerulosclerosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Focal Segmental Glomerulosclerosis Therapies and Key Companies

  • EG-102: Evergreen Therapeutics

  • OCX-063: Certa Therapeutics

  • R3R 01: River 3 Renal Corp

  • BI764198: Boehringer Ingelheim

  • DMX200: Dimerix Bioscience

  • Sparsentan: Travere Therapeutics

  • DMX-200: Dimerix

  • GFB-887: Goldfinch Bio

  • VX-147: Vertex Pharmaceuticals

  • Losmapimod: GlaxoSmithKline

  • Propagermanium: Dimerix Bioscience Pty Ltd

  • RE-021 (Sparsentan): Travere Therapeutics, Inc.

  • CCX140-B: ChemoCentryx

  • Dapagliflozin: AstraZeneca

  • rituximab: Genentech, Inc.

  • fresolimumab: Sanofi

  • Acthar Gel: Mallinckrodt ARD LLC

  • VB119: ACELYRIN Inc.

  • Bleselumab: Kyowa Kirin Co., Ltd.

  • Abatacept: Bristol-Myers Squibb

 

Discover more about therapies set to grab major Focal Segmental Glomerulosclerosis market share @ Focal Segmental Glomerulosclerosis Treatment Market

 

Focal Segmental Glomerulosclerosis Market Drivers

  • Increasing prevalence of chronic kidney diseases and rare glomerular disorders is expanding the patient pool for FSGS therapies.

  • Growing awareness and improved diagnostic capabilities, including genetic testing and kidney biopsy techniques, are supporting earlier and more accurate diagnosis.

  • Advancements in targeted and precision medicine approaches are driving the development of novel therapies aimed at underlying disease mechanisms.

  • A robust pipeline of emerging treatments, including endothelin receptor antagonists, APOL1-targeted therapies, and immunomodulators, is fueling market growth.

 

Focal Segmental Glomerulosclerosis Market Barriers

  • The rarity and heterogeneity of FSGS make patient identification, diagnosis, and clinical trial recruitment challenging.

  • Limited availability of approved disease-specific therapies results in continued reliance on supportive care and off-label treatments.

  • High costs associated with novel therapies and long-term disease management may restrict patient access and reimbursement.

  • Variability in disease progression and treatment response complicates clinical development and therapeutic decision-making.

 

Scope of the Focal Segmental Glomerulosclerosis Market Report

  • Study Period: 2022–2036

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Focal Segmental Glomerulosclerosis Companies: Evergreen Therapeutics, Certa Therapeutics, River 3 Renal Corp, Boehringer Ingelheim, Dimerix Bioscience, Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, GlaxoSmithKline, Dimerix Bioscience Pty Ltd, ChemoCentryx, AstraZeneca, Genentech, Inc., Sanofi, Mallinckrodt ARD LLC, ACELYRIN Inc., Kyowa Kirin Co., Ltd., Bristol-Myers Squibb, and others

  • Key Focal Segmental Glomerulosclerosis Therapies: EG-102, OCX-063, R3R 01, BI764198, DMX-200, GFB-887, VX-147, Losmapimod, Propagermanium, RE-021 (Sparsentan), CCX140-B, Dapagliflozin, rituximab, fresolimumab, Acthar Gel, VB119, Bleselumab, Abatacept, and others

  • Focal Segmental Glomerulosclerosis Therapeutic Assessment: Focal Segmental Glomerulosclerosis current marketed and Focal Segmental Glomerulosclerosis emerging therapies

  • Focal Segmental Glomerulosclerosis Market Dynamics: Focal Segmental Glomerulosclerosis market drivers and Focal Segmental Glomerulosclerosis market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Focal Segmental Glomerulosclerosis Unmet Needs, KOL’s views, Analyst’s views, Focal Segmental Glomerulosclerosis Market Access and Reimbursement

 

To know more about Focal Segmental Glomerulosclerosis companies working in the treatment market, visit @ Focal Segmental Glomerulosclerosis Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Focal Segmental Glomerulosclerosis Market Report Introduction

2. Executive Summary for Focal Segmental Glomerulosclerosis

3. SWOT analysis of Focal Segmental Glomerulosclerosis

4. Focal Segmental Glomerulosclerosis Patient Share (%) Overview at a Glance

5. Focal Segmental Glomerulosclerosis Market Overview at a Glance

6. Focal Segmental Glomerulosclerosis Disease Background and Overview

7. Focal Segmental Glomerulosclerosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Focal Segmental Glomerulosclerosis

9. Focal Segmental Glomerulosclerosis Current Treatment and Medical Practices

10. Focal Segmental Glomerulosclerosis Unmet Needs

11. Focal Segmental Glomerulosclerosis Emerging Therapies

12. Focal Segmental Glomerulosclerosis Market Outlook

13. Country-Wise Focal Segmental Glomerulosclerosis Market Analysis (2022–2036)

14. Focal Segmental Glomerulosclerosis Market Access and Reimbursement of Therapies

15. Focal Segmental Glomerulosclerosis Market Drivers

16. Focal Segmental Glomerulosclerosis Market Barriers

17. Focal Segmental Glomerulosclerosis Appendix

18. Focal Segmental Glomerulosclerosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Focal Segmental Glomerulosclerosis Market Set for Strong Expansion Through 2036 Amid Rising Investment Interest – DelveInsight | Retrophin, AbbVie, AstraZeneca, Pfizer, Sanofi, Teva Pharma

Anal Cancer Market to Witness Transformational Growth Opportunities by 2036 – DelveInsight | Incyte Corp, BioMimetix, Inovio Pharma, Merck Sharp & Dohme, Dustin Deming, Advaxis

The Key Anal Cancer Companies in the market include – Incyte Corporation, BioMimetix, Inovio Pharmaceuticals, Merck Sharp & Dohme, Dustin Deming, Advaxis, Inc., Oryx GmbH & Co. KG, and others.

 

DelveInsight’s “Anal Cancer Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Anal Cancer, historical and forecasted epidemiology as well as the Anal Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

The latest healthcare forecast report provides an in-depth analysis of Anal Cancer, offering comprehensive insights into the Anal Cancer revenue trends, prevalence, and treatment landscape. The report delves into key Anal Cancer statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Anal Cancer therapies. Additionally, we cover the landscape of Anal Cancer clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Anal Cancer treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Anal Cancer space.

 

Get a Free sample for the Anal Cancer Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/anal-cancer-market

 

Some of the key facts of the Anal Cancer Market Report:

  • The Anal Cancer market size was valued at around USD 12 million in 2025 and is anticipated to grow to nearly USD 120 million by 2036, registering a robust CAGR of 24% between 2026 and 2036.

  • In October 2025, Oncolytics Biotech announced updated clinical data for Pelareorep in combination with atezolizumab in previously treated metastatic anal cancer, demonstrating an objective response rate of ~30%, which was more than double historical response rates seen with currently available therapies.

  • In August 2025, Invion Limited announced that the US FDA granted Orphan Drug Designation to INV043 for the treatment of anal cancer, providing incentives to support the development of this therapy for a rare disease.

  • In May 2025, Incyte announced that the FDA had approved ZYNYZ, making it the first and only approved first-line treatment for advanced anal cancer patients in the US. In addition, the FDA approved ZYNYZ as a single agent for the treatment of adult patients with locally recurrent or metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy.

  • Chemoradiotherapy (CRT) remains the standard of care for localized anal cancer, with ongoing research focusing on targeted therapies, immunotherapies, and novel chemotherapeutic agents to improve treatment outcomes.

  • Nivolumab (OPDIVO) and pembrolizumab (KEYTRUDA) are considered second-line immunotherapy options for patients who do not respond to initial treatments.

  • According to DelveInsight’s estimates, in 2025, there were nearly 20,500 incident cases of anal cancer in the 7MM, out of which the US accounted for the highest incident cases in 2025.

  • In EU4 and the UK, females accounted for more incident cases of anal cancer, i.e., nearly 70%, as compared to males with incident cases of nearly 30%, in 2025.

  • In 2025, among EU4 and the UK, Germany accounted for the highest number of cases of anal cancer, whereas Spain accounted for the least number of cases.

  • As per the analysis, in the United States in 2025, anal cancer was found to be more incident in patients aged 65 years and above (~60%), followed by patients aged 50-64 years (~37%), and it was lowest in patients below 50 years (~4%).

  • In 2025, Japan accounted for approximately 1,200 incident cases of anal cancer accounted for approximately, which was significantly lower compared to the EU4 and the US.

  • In Japan, HPV negative (~1, 100 cases) cases of anal cancer were found to be more incident than HPV positive (~100 cases) in 2025

  • Key Anal Cancer Companies: Incyte Corporation, BioMimetix, Inovio Pharmaceuticals, Merck Sharp & Dohme, Dustin Deming, Advaxis, Inc., Oryx GmbH & Co. KG, and others.

  • Key Anal Cancer Therapies: Retifanlimab, BMX-001, VGX-3100, 9vHPV Vaccine, Pembrolizumab, cetuximab, Axalimogene filolisbac, P16_37-63, and others

  • The Anal Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Anal Cancer pipeline products will significantly revolutionize the Anal Cancer market dynamics.

  • The total number of incident cases of anal cancer in the 7MM was around 20,000 in 2023, and this is expected to rise by 2036, growing at a CAGR of 2.4% during the study period (2022–2036).

  • The United States had the highest number of incident cases of anal cancer among the 7MM countries, and this number is expected to grow at a CAGR of 3.6% during the study period from 2022 to 2036.

  • In 2023, around 82% of patients in the United States who tested positive for HPV were diagnosed with anal cancer, with HPV identified as the main contributing factor.

  • In 2023, EU4 and the UK together recorded nearly 9,000 incident cases of anal cancer, a number expected to rise by 2036. Among the EU4 countries, Germany had the highest number of incident cases.

 

Anal Cancer Overview

Anal cancer is a rare type of cancer that develops in the tissues of the anus, the opening at the end of the rectum. It often begins in the squamous cells lining the anal canal. Risk factors include human papillomavirus (HPV) infection, smoking, weakened immune system, and a history of anal or genital warts. Symptoms may include bleeding, pain, itching, or a lump near the anus. Treatment options typically involve surgery, radiation therapy, and chemotherapy, depending on the stage and spread of the cancer. Early detection significantly improves outcomes.

 

To Know in detail about the Anal Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Anal Cancer Market Forecast

 

Anal Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Anal Cancer Epidemiology Segmentation:

The Anal Cancer market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

  • Total Incident Cases of Anal Cancer

  • Gender-specific Cases of Anal Cancer

  • Age-specific Cases of Anal Cancer

  • Histology-specific Cases of Anal Cancer

  • HPV Status-specific Cases of Anal Cancer

  • Stage-specific Cases of Anal Cancer

  • Line-wise Treated Cases of Anal Cancer

 

Download the report to understand which factors are driving Anal Cancer epidemiology trends @ Anal Cancer Epidemiology Forecast

 

Anal Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Anal Cancer market or expected to get launched during the study period. The analysis covers Anal Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Anal Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Anal Cancer Therapies and Key Companies

  • Ficerafusp alfa: Bicara Therapeutics

  • BMX-001: BioMimetix

  • Retifanlimab: Incyte Corporation

  • BMX-001: BioMimetix

  • VGX-3100: Inovio Pharmaceuticals

  • 9vHPV Vaccine: Merck Sharp & Dohme

  • Pembrolizumab: Dustin Deming

  • cetuximab: AIDS Malignancy Consortium

  • Axalimogene filolisbac: Advaxis, Inc.

  • P16_37-63: Oryx GmbH & Co. KG

 

Discover more about therapies set to grab major Anal Cancer market share @ Anal Cancer Treatment Landscape

 

Anal Cancer Market Drivers

  • Increasing incidence of HPV-associated anal cancer, particularly among high-risk populations, is driving demand for effective treatment options.

  • Growing awareness and improved screening practices are facilitating earlier diagnosis and increasing the number of patients entering treatment pathways.

  • Advancements in immunotherapy and targeted therapies are expanding treatment options for advanced and recurrent anal cancer.

  • Rising investment in oncology research and clinical trials is accelerating the development of novel therapeutics for anal cancer.

 

Anal Cancer Market Barriers

  • Relatively low disease prevalence compared to other cancers limits patient populations and may reduce commercial incentives for drug development.

  • Limited availability of approved targeted therapies restricts treatment choices, particularly for advanced or metastatic disease.

  • Challenges in early detection and diagnosis can lead to delayed treatment and poorer clinical outcomes.

  • High treatment costs and reimbursement constraints may hinder access to novel therapies in certain regions.

 

Scope of the Anal Cancer Market Report

  • Study Period: 2022–2036

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Anal Cancer Companies: Incyte Corporation, BioMimetix, Inovio Pharmaceuticals, Merck Sharp & Dohme, Dustin Deming, Advaxis, Inc., Oryx GmbH & Co. KG, and others

  • Key Anal Cancer Therapies: Retifanlimab, BMX-001, VGX-3100, 9vHPV Vaccine, Pembrolizumab, cetuximab, Axalimogene filolisbac, P16_37-63, and others

  • Anal Cancer Therapeutic Assessment: Anal Cancer current marketed and Anal Cancer emerging therapies

  • Anal Cancer Market Dynamics: Anal Cancer market drivers and Anal Cancer market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Anal Cancer Unmet Needs, KOL’s views, Analyst’s views, Anal Cancer Market Access and Reimbursement

 

To know more about Anal Cancer companies working in the treatment market, visit @ Anal Cancer Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Anal Cancer Market Report Introduction

2. Executive Summary for Anal Cancer

3. SWOT analysis of Anal Cancer

4. Anal Cancer Patient Share (%) Overview at a Glance

5. Anal Cancer Market Overview at a Glance

6. Anal Cancer Disease Background and Overview

7. Anal Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Anal Cancer

9. Anal Cancer Current Treatment and Medical Practices

10. Anal Cancer Unmet Needs

11. Anal Cancer Emerging Therapies

12. Anal Cancer Market Outlook

13. Country-Wise Anal Cancer Market Analysis (2022–2036)

14. Anal Cancer Market Access and Reimbursement of Therapies

15. Anal Cancer Market Drivers

16. Anal Cancer Market Barriers

17. Anal Cancer Appendix

18. Anal Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

 

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Anal Cancer Market to Witness Transformational Growth Opportunities by 2036 – DelveInsight | Incyte Corp, BioMimetix, Inovio Pharma, Merck Sharp & Dohme, Dustin Deming, Advaxis

Cytokine Release Syndrome Market Emerging as a High-Growth Healthcare Investment Space Through 2036 – DelveInsight | Incyte, Kite, A Gilead Company, Jazz Pharmaceuticals

The Key Cytokine Release Syndrome Companies in the market include – Genentech, Swedish Orphan Biovitrum (sobi), Incyte, Kite, A Gilead Company, Jazz Pharmaceuticals, Fred Hutchinson Cancer Center, Ontario Clinical Oncology Group, GlaxoSmithKline, UNC Lineberger Comprehensive Cancer Center, SCRI Development Innovations and others.

 

The Cytokine Release Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cytokine Release Syndrome pipeline products will significantly revolutionize the Cytokine Release Syndrome market dynamics.

 

DelveInsight’s “Cytokine Release Syndrome Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Cytokine Release Syndrome, historical and forecasted epidemiology as well as the Cytokine Release Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Cytokine Release Syndrome market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2022 to 2036. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

 

Get a Free sample for the Cytokine Release Syndrome Market Report –

https://www.delveinsight.com/report-store/cytokine-release-syndrome-market

 

Some of the key facts of the Cytokine Release Syndrome Market Report:

  • The Cytokine Release Syndrome market size is projected to grow at a strong CAGR of 22% during the forecast period from 2026 to 2036.

  • In March 2026, Emerging CAR-T Research: Preliminary findings from the Phase I CaMMouflage study of CB-011, an allogeneic BCMA-directed CAR-T cell therapy for multiple myeloma, demonstrated robust and sustained clinical responses alongside a favorable safety profile, highlighting continued progress toward enhancing treatment efficacy while minimizing the risk of Cytokine Release Syndrome (CRS).

  • In February 2026, Phase III Trial Results: The Phase III OLYMPIA-3 trial assessing odronextamab in combination with CHOP for previously untreated diffuse large B-cell lymphoma demonstrated promising clinical efficacy. As bispecific antibodies advance into frontline treatment settings, monitoring and managing Cytokine Release Syndrome (CRS) continues to be a critical aspect of their safety profile.

  • In December 2025, CytoAgents announced that preliminary safety data from its Phase I/II clinical trial would be presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. CTO1681 was shown to be well tolerated at the 10μg three times a day (TID) dose.

  • In December 2025, CytoAgents announced that data from two of its Investigational New Drug (IND) applications enabling studies will be presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025, in the UK. CTO1681 attenuates key cytokines known to drive CRS without compromising the CAR T-Cell-mediated tumor killing in vitro and in vivo.

  • In April 2025, CytoAgents Inc., a clinical-stage biotech company developing CTO1681 for the prevention and treatment of Cytokine Release Syndrome (CRS), has announced the successful completion of the initial dose and dose-limiting toxicity observation period in its ongoing Phase 1b/2a trial. Based on the evaluation of safety and efficacy data, the Safety Review Committee (SRC) has approved advancing to the next higher planned dose in Cohort 2.

  • The frequency and severity of CRS after CAR-T cell therapy vary between products; any grade 37–93%, grade 3 or 4 is around 1–23%.

  • CRS occurs in approximately 43–100% of patients with leukemia or lymphoma receiving CAR-T cell therapy targeting CD19, with variability depending on the therapy and study population.

  • The United States accounted for the highest incident cases of CRS, representing approximately 25% of total cases in the 7MM in 2025.

  • Among the EU4 and the UK, Germany accounted for the highest incidence of CRS in 2025, followed by France, while Spain reported the lowest incidence.

  • Key Cytokine Release Syndrome Companies: Genentech, Swedish Orphan Biovitrum (sobi), Incyte, Kite, A Gilead Company, Jazz Pharmaceuticals, Fred Hutchinson Cancer Center, Ontario Clinical Oncology Group, GlaxoSmithKline, UNC Lineberger Comprehensive Cancer Center, SCRI Development Innovations and others

  • Key Cytokine Release Syndrome Therapies: ACTEMRA/ROACTEMRA (tocilizumab), KINERET (anakinra), Itacitinib, Anakinra & Axicabtagene Ciloleucel, Defibrotide, Anakinra, Elranatamab injection, Otelixizumab, iC9-CAR19 cells, Teclistamab and others

 

Cytokine Release Syndrome Overview

Cytokine release syndrome (CRS) is a systemic inflammatory response that can occur as a result of certain medical treatments, particularly immunotherapies and cell-based therapies like CAR-T cell therapy. During these treatments, immune cells are activated and release large amounts of cytokines, which are signaling molecules that regulate the immune system. In CRS, this immune response becomes dysregulated, leading to an excessive release of cytokines into the bloodstream.

 

To Know in detail about the Cytokine Release Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cytokine Release Syndrome Market Insights

 

Cytokine Release Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Cytokine Release Syndrome Epidemiology Segmentation:

The Cytokine Release Syndrome market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

  • Total Incident Cases of Cytokine Release Syndrome

  • Grade-specific Incident Cases of Cytokine Release Syndrome

  • CRS Cases by CAR-T Therapies

  • CRS Cases by Bispecific Antibodies

  • CRS Cases by Allogeneic Transplant

  • Total Treated Cases of Cytokine Release Syndrome

 

Download the report to understand which factors are driving Cytokine Release Syndrome epidemiology trends @ Cytokine Release Syndrome Epidemiological Insights

 

Cytokine Release Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cytokine Release Syndrome market or expected to get launched during the study period. The analysis covers Cytokine Release Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Cytokine Release Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Cytokine Release Syndrome Therapies and Key Companies

  • Tocilizumab (ACTEMRA): Genentech

  • CTO1681: CytoAgents

  • ACTEMRA/ROACTEMRA (tocilizumab): Genentech

  • KINERET (anakinra): Swedish Orphan Biovitrum (sobi)

  • Itacitinib: Incyte

  • Anakinra & Axicabtagene Ciloleucel: Kite, A Gilead Company

  • Defibrotide: Jazz Pharmaceuticals

  • Anakinra: Fred Hutchinson Cancer Center

  • Elranatamab injection: Ontario Clinical Oncology Group

  • Otelixizumab: GlaxoSmithKline

  • iC9-CAR19 cells: UNC Lineberger Comprehensive Cancer Center

  • Teclistamab: SCRI Development Innovations

 

To know more about Cytokine Release Syndrome treatment, visit @ Cytokine Release Syndrome Medications

 

Cytokine Release Syndrome Market Drivers

  • Growing adoption of CAR-T cell therapies and bispecific antibodies is increasing the incidence of Cytokine Release Syndrome (CRS), driving demand for effective management and treatment options.

  • Rising prevalence of hematologic malignancies and cancers treated with advanced immunotherapies is expanding the CRS patient pool.

  • Advancements in immuno-oncology and cell-based therapies are creating opportunities for novel CRS prevention and treatment approaches.

  • Increasing awareness and improved diagnosis of CRS among healthcare professionals are supporting earlier intervention and better patient outcomes.

 

Cytokine Release Syndrome Market Barriers

  • Limited availability of approved CRS-specific therapies restricts treatment options and may hinder market expansion.

  • High costs associated with CAR-T therapies and CRS management can limit patient access, particularly in cost-sensitive healthcare systems.

  • Complexity in diagnosing and grading CRS severity may lead to variability in treatment approaches across healthcare settings.

  • Potential safety concerns and adverse effects

 

Scope of the Cytokine Release Syndrome Market Report

  • Study Period: 2022–2036

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Cytokine Release Syndrome Companies: Genentech, Swedish Orphan Biovitrum (sobi), Incyte, Kite, A Gilead Company, Jazz Pharmaceuticals, Fred Hutchinson Cancer Center, Ontario Clinical Oncology Group, GlaxoSmithKline, UNC Lineberger Comprehensive Cancer Center, SCRI Development Innovations, and others

  • Key Cytokine Release Syndrome Therapies: ACTEMRA/ROACTEMRA (tocilizumab), KINERET (anakinra), Itacitinib, Anakinra & Axicabtagene Ciloleucel, Defibrotide, Anakinra, Elranatamab injection, Otelixizumab, iC9-CAR19 cells, Teclistamab, and others

  • Cytokine Release Syndrome Therapeutic Assessment: Cytokine Release Syndrome current marketed and Cytokine Release Syndrome emerging therapies

  • Cytokine Release Syndrome Market Dynamics: Cytokine Release Syndrome market drivers and Cytokine Release Syndrome market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Cytokine Release Syndrome Unmet Needs, KOL’s views, Analyst’s views, Cytokine Release Syndrome Market Access and Reimbursement

 

Discover more about therapies set to grab major Cytokine Release Syndrome market share @ Cytokine Release Syndrome Treatment Landscape

 

Table of Contents

1. Cytokine Release Syndrome Market Report Introduction

2. Executive Summary for Cytokine Release Syndrome

3. SWOT analysis of Cytokine Release Syndrome

4. Cytokine Release Syndrome Patient Share (%) Overview at a Glance

5. Cytokine Release Syndrome Market Overview at a Glance

6. Cytokine Release Syndrome Disease Background and Overview

7. Cytokine Release Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Cytokine Release Syndrome

9. Cytokine Release Syndrome Current Treatment and Medical Practices

10. Cytokine Release Syndrome Unmet Needs

11. Cytokine Release Syndrome Emerging Therapies

12. Cytokine Release Syndrome Market Outlook

13. Country-Wise Cytokine Release Syndrome Market Analysis (2022–2036)

14. Cytokine Release Syndrome Market Access and Reimbursement of Therapies

15. Cytokine Release Syndrome Market Drivers

16. Cytokine Release Syndrome Market Barriers

17. Cytokine Release Syndrome Appendix

18. Cytokine Release Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cytokine Release Syndrome Market Emerging as a High-Growth Healthcare Investment Space Through 2036 – DelveInsight | Incyte, Kite, A Gilead Company, Jazz Pharmaceuticals

Dry Age-Related Macular Degeneration Market is Projected to Grow at ~19.2% CAGR by 2036, Estimates DelveInsight

Key companies like Astellas Pharma/Iveric Bio, Apellis Pharmaceuticals, Belite Bio, Alkeus Pharmaceuticals, Aviceda Therapeutics, Allegro Ophthalmics, Johnson & Johnson Innovative Medicine, and others are leading the exponential growth in the market.

DelveInsight’s “Dry Age-Related Macular Degeneration Market Insight, Epidemiology and Market Forecast – 2036” report delivers an in-depth understanding of Dry Age-Related Macular Degeneration (AMD), historical and forecasted epidemiology as well as the Dry AMD market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Intersted to know which drug will capture the highest market share, download report to understand dryAMD drug market update @ https://www.delveinsight.com/report-store/dry-age-macular-degeneration-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Key Takeaways from the Dry Age-Related Macular Degeneration Market Report

  • The Dry Age-Related Macular Degeneration (AMD) market across the 7MM is expected to witness significant growth during the forecast period, driven by increasing disease prevalence, improved diagnosis rates, and the emergence of novel therapies targeting other indications like geographic atrophy (GA).

  • Emerging therapies such as Tinlarebant (LBS-008), Gildeuretinol acetate (ALK-001), AVD-104, Risuteganib (ALG-1001), JNJ-1887, and others are expected to intensify competition by offering differentiated mechanisms of action, improved durability, and the potential to reduce treatment burden compared with chronic intravitreal injections.

  • Gene therapies and regenerative medicine candidates are attracting substantial industry interest due to their potential to provide long-term efficacy through one-time administration, a key factor influencing future market share and physician adoption.

  • In 2025, the total prevalent cases of AMD across the 7MM were estimated at over 72 million, with the patient population expected to increase through 2036.

  • The United States accounted for the largest geographic atrophy patient population among the 7MM, with approximately 0.8 million prevalent cases in 2025.

  • In the US, the highest burden of geographic atrophy was observed among patients aged 85 years and older, followed by those aged 65–84 years in 2025.

  • The late-stage AMD population in the US was estimated at nearly 1.9 million cases in 2025.

  • The leading Dry AMD Companies include Astellas Pharma/Iveric Bio, Apellis Pharmaceuticals, Belite Bio, Alkeus Pharmaceuticals, Aviceda Therapeutics, Allegro Ophthalmics, Johnson & Johnson Innovative Medicine, and others.

  • Despite recent therapeutic advances, substantial unmet needs remain in Dry AMD, visual function preservation, retinal regeneration, and early disease intervention, creating significant opportunities for pipeline developers and investors, understand through this report how to materialise these unmet needs and gain competitive advantage.

Gain a competitive edge in the Dry Age-Related Macular Degeneration Market by exploring our in-depth analysis @ Dry AMD Treatment Drugs https://www.delveinsight.com/report-store/dry-age-macular-degeneration-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Dry Age-Related Macular Degeneration Epidemiology Segmentation in the 7MM

DelveInsight’s market report is buit on robust Dry AMD epidemiology analysis providing detailed historical and forecasted patient population insights across the 7MM (United States, EU4, the United Kingdom, and Japan), including:

  • Total Prevalent Cases of AMD: Assessment of the overall AMD patient population to quantify the disease burden and market opportunity across major markets.

  • Stage-specific Prevalent Cases of AMD: Detailed segmentation of AMD patients into early, intermediate, and late-stage disease, helping stakeholders understand disease progression trends.

  • Total Prevalent Cases of Geographic Atrophy (GA): Analysis of the GA patient population, representing the advanced form of Dry AMD and a key target population for emerging therapies.

  • Total Prevalent Cases of Dry AMD: Comprehensive evaluation of patients affected by Dry AMD across the 7MM.

  • Total Diagnosed Prevalent Cases of Dry AMD: Estimation of the diagnosed patient pool, providing insights into treatment accessibility and commercial opportunity.

  • Age-specific Cases of Early and Intermediate AMD: Breakdown of patients by age groups to identify populations at greater risk of disease progression and future treatment demand.

  • Age-specific Cases of Geographic Atrophy: Analysis of GA prevalence across different age cohorts, supporting patient segmentation and market forecasting.

  • Geographic Atrophy Cases by Visual Impairment: Assessment of GA patients based on the severity of visual impairment, enabling evaluation of disease burden, treatment eligibility, and unmet medical needs.

  • 7MM Epidemiology Forecast (2022–2036): Long-term projections of patient population trends to support market sizing, launch planning, business development, and investment decisions.

  • Country-specific Epidemiology Insights: Granular patient population estimates across the US, Germany, France, Italy, Spain, the United Kingdom, and Japan to identify high-value markets and growth opportunities.

These epidemiological insights help pharmaceutical companies, investors, business development teams, and strategy leaders evaluate the future growth potential of the Dry AMD and Geographic Atrophy markets while supporting data-driven commercial and pipeline decisions.

Download the report to understand which factors are driving Dry Age-Related Macular Degeneration Epidemiology Trends @ Dry Age-Related Macular Degeneration Prevalence https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Marketed Dry Age-Related Macular Degeneration Drugs: The marketed DryAMD landscape remains relatively nascent but is rapidly evolving following the introduction of novel therapies for Geographic Atrophy. The launch of these products has validated the commercial potential of the market and paved the way for emerging therapies with differentiated mechanisms of action and improved efficacy profiles.

  • IZERVAY (Avacincaptad pegol): Astellas Pharma/Iveric Bio

Avacincaptad pegol (IZERVAY) is a novel ophthalmic therapy developed by Iveric Bio and later commercialized under Astellas Pharma following its acquisition of Iveric Bio in 2023. It is an RNA aptamer-based drug designed for the treatment of geographic atrophy secondary to AMD. The drug received US FDA approval in August 2023, marking a significant milestone as one of the first disease-modifying therapies targeting dry AMD progression. Avacincaptad pegol is administered as a monthly intravitreal injection into the affected eye. Its approval was based on Phase III trials (GATHER1 and GATHER2), which demonstrated a statistically significant reduction in the rate of geographic atrophy lesion growth compared with sham treatment.

  • SYFOVRE (Pegcetacoplan): Apellis Pharmaceuticals

Pegcetacoplan (SYFOVRE) is a first-in-class complement inhibitor approved for the treatment of geographic atrophy secondary to AMD. It targets complement component C3, a central protein in the complement cascade. Administered via intravitreal injection either monthly or every other month, SYFOVRE demonstrated clinically meaningful reductions in GA lesion growth in Phase III (OAKS and DERBY) trials, with increasing efficacy observed over time. While it does not restore lost vision, it significantly slows disease progression.

Emerging Dry Age-Related Macular Degeneration Drugs

  • Tinlarebant (LBS-008): Belite Bio

Tinlarebant is a novel oral therapy intended to reduce the accumulation of vitamin A-based toxins (known as bisretinoids) that contribute to disease progression in geographic atrophy. Bisretinoids are by-products of the visual cycle, which is dependent on the supply of vitamin A (retinol) to the eye. Tinlarebant works by reducing and maintaining levels of serum retinol binding protein 4 (RBP4), the sole carrier protein for retinol transport from the liver to the eye. The therapy is currently in Phase III clinical development.

  • Gildeuretinol acetate (ALK-001): Alkeus Pharmaceuticals

Oral gildeuretinol acetate (ALK-001) is a new molecular entity designed to reduce the dimerization of vitamin A without modulating the visual cycle. Gildeuretinol is being evaluated in clinical trials for the treatment of Stargardt disease and has been studied for geographic atrophy secondary to age-related macular degeneration. The therapy is currently in Phase III clinical development.

Latest highlights from dAMD market:

  • On March 24, 2026, Ocugen reported topline 12-month results from the Phase II ArMaDa trial, demonstrating a statistically significant 31% reduction in GA lesion growth at the dose selected for Phase III development. The study also showed photoreceptor preservation and a favorable safety profile, supporting advancement into a registrational program. Ocugen announced plans to initiate a Phase III trial in Q3 2026, positioning OCU410 among the most advanced late-stage gene therapies for Geographic Atrophy. The update further strengthened its commercial potential and competitive positioning against SYFOVRE and IZERVAY.

  • On January 28, 2026, Eyestem Research announced that it had received CDSCO approval to initiate a Phase II randomized controlled trial of Eyecyte-RPE in patients with geographic atrophy associated with Dry AMD. The retinal pigment epithelium cell therapy is designed to restore retinal function through regenerative medicine, offering a differentiated approach from complement inhibitors and gene therapies. The regulatory milestone highlights increasing industry interest in cell-based therapies and expands the competitive landscape of the Geographic Atrophy market.

  • In December 2025, Alkeus Pharmaceuticals announced that data from its clinical studies of investigational oral gildeuretinol for the treatment of geographic atrophy will be presented at the 13th International FLORetina ICOOR Congress at the Fortezza de Basso in Florence, Italy.

  • In July 2025, Alkeus Pharmaceuticals announced that data from its clinical studies of investigational oral gildeuretinol for the treatment of geographic atrophy secondary to AMD (SAGA) will be presented during the American Society of Retina Specialists (ASRS) 43rd Annual Scientific Meeting.

  • In February 2025, Alkeus Pharmaceuticals announced that results from its clinical studies of investigational oral gildeuretinol for the treatment of geographic atrophy secondary to AMD (SAGA) will be presented at the 48th Annual Meeting of the Macula Society.

Discover key developments and opportunities in the Dry Age-Related Macular Degeneration Market @ Dry Age-Related Macular Degeneration Market Size – https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Dry Age-Related Macular Degeneration Companies

Dry Age-Related Macular Degeneration Companies include Astellas Pharma/Iveric Bio, Apellis Pharmaceuticals, Belite Bio, Alkeus Pharmaceuticals, Aviceda Therapeutics, Allegro Ophthalmics, Johnson & Johnson Innovative Medicine, and others.

Dry Age-Related Macular Degeneration Market Outlook

The treatment landscape for Dry Age-Related Macular Degeneration has historically been limited to supportive care, primarily involving nutritional supplementation (e.g., AREDS formulations), lifestyle modifications, and visual aids to slow disease progression and manage symptoms. The approved therapies – Avacincaptad pegol (IZERVAY) and Pegcetacoplan (SYFOVRE) – both target the complement cascade and represent a paradigm shift toward mechanism-based treatment by slowing the progression of geographic atrophy, although they do not restore lost vision and require regular intravitreal administration.

The pipeline for Dry Age-Related Macular Degeneration is rapidly evolving, with emerging therapies focusing on novel biological pathways beyond complement inhibition. Tinlarebant (LBS-008) is an oral therapy designed to reduce the accumulation of toxic vitamin A byproducts in the retina, thereby addressing a key driver of retinal degeneration. Similarly, Gildeuretinol acetate (ALK-001) targets vitamin A dimerization to prevent the formation of harmful retinal deposits. AVD-104 utilizes glycoimmune modulation to reduce inflammation and protect retinal cells. These therapies highlight a shift toward oral and less invasive treatment options, alongside innovative mechanisms targeting metabolic and inflammatory pathways. Overall, the emergence of both approved complement inhibitors and a diverse pipeline of targeted therapies marks a significant transition from supportive care to disease-modifying strategies in dry AMD.

Download DelveInsight’s Dry Age-Related Macular Degeneration Market report today and stay ahead in this rapidly evolving field @ Dry Age-Related Macular Degeneration Clinical Trials https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Scope of the Dry Age-Related Macular Degeneration Market Report

  • Coverage: 7MM

  • Study Period: 2022–2036

  • Dry Age-Related Macular Degeneration Companies: Astellas Pharma/Iveric Bio, Apellis Pharmaceuticals, Belite Bio, Alkeus Pharmaceuticals, Aviceda Therapeutics, Allegro Ophthalmics, Johnson & Johnson Innovative Medicine, and others.

  • Dry Age-Related Macular Degeneration Pipeline Therapies: Tinlarebant (LBS-008), Gildeuretinol acetate (ALK-001), AVD-104, Risuteganib (ALG-1001), JNJ-1887, and others.

  • Dry Age-Related Macular Degeneration Competitive Intelligence Analysis: SWOT analysis and Conjoint analysis and Market entry strategies

  • Dry Age-Related Macular Degeneration Unmet Needs, KOL’s views, Analyst’s views, Dry Age-Related Macular Degeneration Market Access and Reimbursement

Table of Contents

  1. Key Insights

  2. Report Introduction

  3. Executive Summary

  4. Key Events

  5. Epidemiology and Market Methodology of Dry Age-related Macular Degeneration (AMD)

  6. Dry Age-related Macular Degeneration (AMD) Market Overview at a Glance

  7. Disease Background and Overview of Dry Age-related Macular Degeneration (AMD)

  8. Epidemiology and Patient Population of Dry Age-related Macular Degeneration (AMD)

  9. Patient Journey of Dry Age-related Macular Degeneration (AMD)

  10. Marketed Therapies

  11. Emerging Therapies

  12. Dry Age-related Macular Degeneration (AMD): Seven Major Market Analysis

  13. Unmet Needs of Dry Age-related Macular Degeneration (AMD)

  14. SWOT Analysis of Dry Age-related Macular Degeneration (AMD)

  15. KOL Views of Dry Age-related Macular Degeneration (AMD)

  16. Market Access and Reimbursement of Dry Age-related Macular Degeneration (AMD)

  17. Appendix

  18. DelveInsight Capabilities

  19. Disclaimer

  20. About DelveInsight

How DelveInsight’s Dry AMD Market Report Helps CXOs and Business Leaders

  • Evaluate the current and future market opportunity across the United States, EU4, the United Kingdom, and Japan through detailed epidemiology and market forecasts.

  • Benchmark emerging assets through comprehensive competitive intelligence, pipeline assessment, clinical trial analysis, and probability of success evaluation.

  • Identify potential licensing, acquisition, co-development, and partnership opportunities by tracking key innovators and late-stage pipeline assets.

  • Assess the impact of upcoming clinical readouts, regulatory milestones, and expected launches on future market share, pricing, reimbursement, and commercial strategy.

  • Support strategic decision-making with insights into KOL perspectives, unmet needs, treatment algorithms, patient segmentation, and evolving market dynamics across the Dry AMD and Geographic Atrophy landscape.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dry Age-Related Macular Degeneration Market is Projected to Grow at ~19.2% CAGR by 2036, Estimates DelveInsight

Fuchs Endothelial Corneal Dystrophy Market Shows Strong Growth Potential with Emerging Therapeutics by 2036 – DelveInsight | Kowa Pharmaceuticals, Trefoil Therapeutics, Santen

DelveInsight’s “Fuchs Endothelial Corneal Dystrophy Market Insights, Epidemiology, and Market Forecast-2036” report offers an in-depth understanding of Fuchs Endothelial Corneal Dystrophy, historical and forecasted epidemiology as well as the FECD market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The Key Fuchs Endothelial Corneal Dystrophy Companies in the market include – Kowa Pharmaceuticals, Trefoil Therapeutics, Santen, ActualEyes, Alcon, Emmecell, AJL Ophthalmic SA, Massachusetts Eye and Ear, KeraMed, Inc, Presbia Plc., and others.

Get a Free sample for the Fuchs Endothelial Corneal Dystrophy Market Report

Some of the key facts of the Fuchs Endothelial Corneal Dystrophy Market Report:

The Fuchs Endothelial Corneal Dystrophy market size was valued at around USD 858 million in 2023 and is anticipated to witness significant growth during the forecast period from 2026 to 2036.

In 2025, the total diagnosed prevalent cases of FECD in the 7MM were approximately 19.3 million. These cases are projected to increase further during the study period (2022–2036).

Among the 7MM, the US accounted for the largest market size of Fuchs Endothelial Corneal Dystrophy with approximately USD 394 million in 2023.

In 2025, the United States accounted for the highest proportion of diagnosed prevalent cases of FECD with approximately 6.6 million cases throughout the 7MM. This was followed by Japan, with about 3.2 million cases, while Spain accounted for the lowest cases at approximately 1.4 million.

Among EU4 and the UK, Germany accounted for the largest market of Fuchs Endothelial Corneal Dystrophy with nearly USD 88 million in 2023, followed by Italy with nearly USD 67 million, while Spain accounted for the least with around USD 50 million.

There is a higher prevalence among females across the 7MM. In the US in 2025, approximately 6 million cases among males and 10.8 million cases among females were accounted, indicating a female predominance.

FECD is a progressive hereditary disease affecting the cornea’s endothelial layer, characterized by corneal edema, guttae formation, reduced visual acuity, and can potentially lead to corneal blindness.

The total market size of the Fuchs Endothelial Corneal Dystrophy treatment market is anticipated to experience growth during the forecast period due to the emergence of new and effective treatments, namely, Ripasudil/K-321, TTHX1114/NM141, STN1010904/AE-001, and others.

Key Fuchs Endothelial Corneal Dystrophy Companies: Kowa Pharmaceuticals, Trefoil Therapeutics, Santen, ActualEyes, Alcon, Emmecell, AJL Ophthalmic SA, Massachusetts Eye and Ear, KeraMed, Inc, Presbia Plc., and others

Key Fuchs Endothelial Corneal Dystrophy Therapies: Ripasudil (K-321), TTHX1114 (NM141), STN1010904/AE-001 (sirolimus), and others

The Fuchs Endothelial Corneal Dystrophy epidemiology based on gender analyzed that FECD occurs in both men and women, with a higher prevalence among females across the 7MM.

The Fuchs Endothelial Corneal Dystrophy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage FECD pipeline products will significantly revolutionize the FECD market dynamics.

Fuchs Endothelial Corneal Dystrophy Overview

Fuchs Endothelial Corneal Dystrophy (FECD) is a progressive hereditary disease affecting the cornea’s endothelial layer. It is characterized by corneal edema, guttae formation, reduced visual acuity, and can lead to corneal blindness. FECD is more common in women, and its prevalence varies geographically in the 7MM. FECD is associated with genetic factors, with mutations in genes like COL8A2, SLC4A11, TCF4, and ZEB1 implicated in its development.

To Know in detail about the Fuchs Endothelial Corneal Dystrophy market outlook, drug uptake, treatment scenario and epidemiology trends, Fuchs Endothelial Corneal Dystrophy Market Forecast: https://www.delveinsight.com/report-store/fuchs-endothelial-corneal-dystrophy-fecd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr

Fuchs Endothelial Corneal Dystrophy Epidemiology

The Fuchs Endothelial Corneal Dystrophy epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Fuchs Endothelial Corneal Dystrophy Epidemiology Segmentation:

The Fuchs Endothelial Corneal Dystrophy market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

  • Total Diagnosed Prevalent Cases of Fuchs Endothelial Corneal Dystrophy (FECD) in the 7MM

  • Gender-specific Cases of Fuchs Endothelial Corneal Dystrophy (FECD) in the 7MM

  • Age-specific Cases of Fuchs Endothelial Corneal Dystrophy (FECD) in the 7MM

  • Grade-specific Cases of Fuchs Endothelial Corneal Dystrophy (FECD) in the 7MM

Download the report to understand which factors are driving Fuchs Endothelial Corneal Dystrophy epidemiology trends @ Fuchs Endothelial Corneal Dystrophy Epidemiology Forecast

Fuchs Endothelial Corneal Dystrophy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Fuchs Endothelial Corneal Dystrophy market or expected to get launched during the study period. The analysis covers FECD market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Fuchs Endothelial Corneal Dystrophy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Fuchs Endothelial Corneal Dystrophy Therapies and Key Companies

Ripasudil (K-321): Kowa Pharmaceuticals – A rho-kinase inhibitor currently in Phase III of clinical development for the treatment of FECD.

TTHX1114 (NM141): Trefoil Therapeutics – An engineered fibroblast growth factor-1 variant designed to protect corneal endothelial cells from stress and injury. Trefoil announced positive Phase II (STORM) trial results showing corneal regeneration and vision recovery.

STN1010904/AE-001 (sirolimus): Santen/ActualEyes – An mTOR inhibitor eye drop that suppresses the formulation of guttae and apoptosis of endothelial cells. Currently being evaluated in Phase IIa of clinical trials.

Discover more about therapies set to grab major FECD market share @ https://www.delveinsight.com/report-store/fuchs-endothelial-corneal-dystrophy-fecd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr

Fuchs Endothelial Corneal Dystrophy Market Drivers

Increasing Disease Prevalence and Patient Awareness: Rising awareness about Fuchs Endothelial Corneal Dystrophy may increase market size in the coming years, resulting in an increase in the prevalence of FECD patients seeking diagnosis and treatment.

Advancement in Diagnostic Techniques: Development of improved diagnostic tools such as deep learning algorithms, Scheimpflug tomography, and anterior segment optical coherence tomography (AS-OCT) are enhancing early detection capabilities and disease monitoring.

Emergence of Innovative Therapeutics: The development of novel treatment approaches including rho-kinase inhibitors and engineered growth factors represents a significant shift from symptomatic management to disease-modifying therapies.

Growing Unmet Medical Needs: Current treatment options provide only temporary symptomatic relief without addressing the underlying cause of endothelial layer dysfunction, creating substantial opportunities for disease-modifying therapies.

Fuchs Endothelial Corneal Dystrophy Market Barriers

Limited Approved Treatment Options: The market currently lacks disease-modifying therapies approved specifically for FECD, with treatment options limited primarily to symptomatic management with topical sodium chloride and steroids.

High Cost of Novel Therapies: The high cost of emerging therapies for the treatment is a major factor restraining the growth of the market, increasing the economic burden on patients and limiting accessibility.

Diagnostic Challenges: Although various diagnostic tools have been developed, there is still a need to improve the availability and accessibility of image analysis tools for early detection, monitoring of disease progression, and customized therapeutic interventions.

Complex Disease Mechanism: FECD is influenced by genetic factors and multiple pathophysiological mechanisms, making treatment development and drug efficacy demonstration challenging.

Patient Accessibility Issues: Geographic variations in disease prevalence and disparities in access to advanced diagnostic and therapeutic options remain significant barriers to market expansion.

Scope of the Fuchs Endothelial Corneal Dystrophy Market Report

Study Period: 2022–2036

Coverage: 7MM [The United States, EU4 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Key Fuchs Endothelial Corneal Dystrophy Companies: Kowa Pharmaceuticals, Trefoil Therapeutics, Santen, ActualEyes, Alcon, Emmecell, AJL Ophthalmic SA, Massachusetts Eye and Ear, KeraMed, Inc, Presbia Plc., and others

Key Fuchs Endothelial Corneal Dystrophy Therapies: Ripasudil (K-321), TTHX1114 (NM141), STN1010904/AE-001 (sirolimus), and others

Fuchs Endothelial Corneal Dystrophy Therapeutic Assessment: FECD current marketed and FECD emerging therapies

Fuchs Endothelial Corneal Dystrophy Market Dynamics: FECD market drivers and FECD market barriers

Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

Fuchs Endothelial Corneal Dystrophy Unmet Needs, KOL’s views, Analyst’s views, FECD Market Access and Reimbursement

To know more about Fuchs Endothelial Corneal Dystrophy companies working in the treatment market, visit @ Fuchs Endothelial Corneal Dystrophy Clinical Trials and Therapeutic Assessment

Table of Content

1 Key Insights

2 Report Introduction

3 FECD Market Overview at a Glance

4 Methodology of FECD Epidemiology and Market

5 Executive Summary of FECD

6 Key Events

7 Disease Background and Overview

8 Epidemiology and Patient Population

9 Patient Journey

10 Emerging Drugs

11 FECD: Market Analysis

12 KOL Views

13 SWOT Analysis

14 Unmet Needs

15 Market Access

16 Appendix

17 DelveInsight Capabilities

18 Disclaimer

19 About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Mehul Malhotra

Email: info@delveinsight.com

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com

Media Contact
Company Name: DelveInsight
Contact Person: Mehul Malhotra
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Fuchs Endothelial Corneal Dystrophy Market Shows Strong Growth Potential with Emerging Therapeutics by 2036 – DelveInsight | Kowa Pharmaceuticals, Trefoil Therapeutics, Santen

Chronic Obstructive Pulmonary Disease Pipeline Shows Strong Momentum as 65+ Pharma Companies in the Race | DelveInsight

DelveInsight’s “Chronic Obstructive Pulmonary Disease Pipeline Insight 2026” report provides comprehensive insights about 65+ companies and 75+ pipeline drugs in the Chronic Obstructive Pulmonary Disease pipeline landscape. It covers the Chronic Obstructive Pulmonary Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Obstructive Pulmonary Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead in understanding the COPD Treatment Landscape @ https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-pipeline-insight

Key Takeaways from the Chronic Obstructive Pulmonary Disease Pipeline Report

  • On June 03, 2026- Hoffmann-La Roche initiated a phase III study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmonary disease (COPD) who have completed the 52-week placebo-controlled treatment period in parent studies GB43311 or GB44332.
  • On May 27, 2026- Sanofi conducted a Phase 4 study with 2 treatment groups. The purpose of this study is to assess the effect of dupilumab compared with placebo on airway inflammation, resistance, and remodeling including mucus plugging and its association with improvement on lung function, exacerbations, and quality of life improvement in participants aged 40 years of age up to 85 years of age (inclusive).
  • DelveInsight’s Chronic Obstructive Pulmonary Disease pipeline report depicts a robust space with 65+ active players working to develop 75+ pipeline therapies for Chronic Obstructive Pulmonary Disease treatment.
  • The leading Chronic Obstructive Pulmonary Disease Companies such as Sanofi, AstraZeneca, Amgen, Synairgen, GlaxoSmithKline, Eisai, Meridigen Biotech, Chiesi, EmeraMed Limited, Verona Pharma, Tetherex Pharmaceuticals, Mereo BioPharma and others.
  • Promising Chronic Obstructive Pulmonary Disease Pipeline Therapies such as QVA149, NVA237, Tiotropium, PF-00610355, Astegolimab, Formoterol Fumarate, TQC2731, Aclidinium bromide and others.

Gain in-depth knowledge of key COPD clinical trials, emerging drugs, and market opportunities @ Chronic Obstructive Pulmonary Disease Clinical Trials Assessment

Chronic Obstructive Pulmonary Disease Overview

Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable disease. It is a poorly reversible lung disease characterized by persistent and progressive airflow limitation caused by an enhanced chronic inflammatory response in the airways and the lungs due to noxious particles or gases. Also, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) defines a COPD exacerbation as an event in the natural course of the disease that is characterized by a change in the patient’s baseline dyspnea, cough, and sputum that is beyond normal day-to-day variations, is acute in onset, and warrants a change in regular medication. Predominantly, COPD includes emphysema and chronic bronchitis.

Chronic Obstructive Pulmonary Disease Emerging Drugs Profile

  • Benralizumab: AstraZeneca

Benralizumab is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that specifically binds to the alpha chain of the interleukin-5 receptor (IL-5R) expressed on eosinophils and basophils. It inhibits the binding of IL-5 as well as the hetero-oligomerization of the alpha and beta subunits of the IL-5R, thus blocking, signal transduction. Besides, it is an afucosylated IgG, which gives it a high affinity for the FcγRIIIα receptor in natural killer cells, macrophages, and neutrophils. In the TH2-high phenotype, IL-5 presents a central role as it is responsible for eosinophil differentiation, survival, activation, and migration to the lungs. The drug is currently in Phase III stage of its clinical trial evaluation to treat COPD.

  • Dupilumab: Sanofi

Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL) that induce inflammatory and immunological reactions in several atopic or allergic conditions, such as eczema, allergic reactions, and rhinosinusitis. Dupilumab was generated by recombinant DNA technology in Chinese Hamster Ovary cell suspension culture. Dupilumab is under investigation for its potential therapeutic use in chronic obstructive pulmonary disease and is currently in the Phase III stage of development.

  • Tezepelumab: Amgen

Tezepelumab (Tezspire) is a first-in-class human monoclonal antibody that works on the primary source of inflammation: the airway epithelium, which is the first point of contact for viruses, allergens, pollutants, and other environmental insults. Specifically, TEZSPIRE targets and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic, and other types of airway inflammation associated with severe asthma. TSLP is released in response to multiple triggers associated with asthma exacerbations, including allergens, viruses, and other airborne particles. Expression of TSLP is increased in the airways of patients with asthma and has been correlated with disease severity. Blocking TSLP may prevent the release of pro-inflammatory cytokines by immune cells, resulting in the prevention of asthma exacerbations and improved asthma control. Tezspire is being developed in collaboration with AstraZeneca and is currently being evaluated in Phase II to treat patients with chronic obstructive pulmonary disease.

  • SNG001: Synairgen

SNG001 boosts antiviral responses in the lungs, has a beneficial effect on lung function, and in more difficult to treat patients, improves asthma control during cold infections. The drug is currently being evaluated in the Phase II stage of development to treat patients with COPD.

  • GSK3923868: GlaxoSmithKline

GSK3923868, is a PI4kβ inhibitor in development as a treatment for viral COPD exacerbations. It belongs to the class of antiasthmatics. The drug acts as a 1-phosphatidylinositol-4-kinase inhibitor. Currently, the drug is in Phase I of its clinical trial evaluation for the treatment of chronic obstructive pulmonary disease.

The Chronic Obstructive Pulmonary Disease Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Obstructive Pulmonary Disease with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Obstructive Pulmonary Disease Treatment.
  • Chronic Obstructive Pulmonary Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Chronic Obstructive Pulmonary Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Obstructive Pulmonary Disease market

Uncover critical updates on therapeutic innovations and their potential impact on patients @ Chronic Obstructive Pulmonary Disease Unmet Needs

Chronic Obstructive Pulmonary Disease Companies

Sanofi, AstraZeneca, Amgen, Synairgen, GlaxoSmithKline, Eisai, Meridigen Biotech, Chiesi, EmeraMed Limited, Verona Pharma, Tetherex Pharmaceuticals, Mereo BioPharma and others.

Chronic Obstructive Pulmonary Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Intramuscular

Chronic Obstructive Pulmonary Disease Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide

Transform your understanding of the COPD Pipeline! @ Chronic Obstructive Pulmonary Disease Market Drivers and Barriers, and Future Perspectives

Scope of the Chronic Obstructive Pulmonary Disease Pipeline Report

  • Coverage- Global
  • Chronic Obstructive Pulmonary Disease Companies- Sanofi, AstraZeneca, Amgen, Synairgen, GlaxoSmithKline, Eisai, Meridigen Biotech, Chiesi, EmeraMed Limited, Verona Pharma, Tetherex Pharmaceuticals, Mereo BioPharma and others.
  • Chronic Obstructive Pulmonary Disease Pipeline Therapies- QVA149, NVA237, Tiotropium, PF-00610355, Astegolimab, Formoterol Fumarate, TQC2731, Aclidinium bromide and others.
  • Chronic Obstructive Pulmonary Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Chronic Obstructive Pulmonary Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Access the Full Chronic Obstructive Pulmonary Disease Pipeline Analysis Today! @ Chronic Obstructive Pulmonary Disease Drugs and Companies

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Chronic Obstructive Pulmonary Disease: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Chronic Obstructive Pulmonary Disease– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Benralizumab: AstraZeneca
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Tezepelumab: Amgen
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. GSK3923868: GlaxoSmithKline
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Chronic Obstructive Pulmonary Disease- Unmet Needs
  21. Chronic Obstructive Pulmonary Disease- Market Drivers and Barriers
  22. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Obstructive Pulmonary Disease Pipeline Shows Strong Momentum as 65+ Pharma Companies in the Race | DelveInsight

CAR-T Pipeline Expands as 180+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s “CAR T-Cell Therapy Pipeline Insight 2026” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in the CAR T-Cell Therapy pipeline landscape. It covers the CAR T-Cell Therapy Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the CAR T-Cell Therapy Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the CAR T-Cell Therapy Pipeline? @ https://www.delveinsight.com/sample-request/chimeric-antigen-receptor-t-cell-therapy-car-t-pipeline-insight

Key Takeaways from the CAR T-Cell Therapy Pipeline Report

  • On June 01, 2026- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company initiated a phase 2 study is to evaluate the efficacy, safety and drug levels of CC-97540 in participants with active systemic lupus erythematosus (SLE) including lupus nephritis with inadequate response to glucocorticoids and at least 2 immunosuppressants.
  • On May 27, 2026- Novartis Pharmaceuticals announced a Phase I/II, open-label, non-randomized, multi-center study in patients with extensive-stage small cell lung cancer (ES-SCLC) to determine the recommended dose(s) (RD) and to evaluate the safety, tolerability and preliminary efficacy of DJI136.
  • On May 26, 2026- Abramson Cancer Center at Penn Medicine conducted a phase II study is being conducted to test the safety and effectiveness of the experimental drug mosunetuzumab (Cohort 1) or obinutuzumab and glofitamab (Cohort 2) when given after CAR (genetically modified) T cells. The study is for patients who have already received a CAR T-cell infusion. Some patients who join the study will receive mosunetuzumab, other patients later in the study may receive a different experimental drug (glofitamab, in combination with obinutuzumab).
  • On May 22, 2026- AstraZeneca initiated a Phase I/II study will evaluate the safety, tolerability, antitumour activity, cellular kinetics, pharmacodynamics, and immunogenicity of AZD5851 in adult participants with GPC3+ advanced/recurrent HCC, where at least one line of prior therapy has failed/or was intolerable, or participant/investigator decision.
  • DelveInsight’s CAR T-Cell Therapy Pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for CAR T-Cell Therapy treatment.
  • The leading CAR T-Cell Therapy Companies such as Caribou Biosciences, Allogene Therapeutics, Synthekine, Shanghai Simnova Biotechnology, Sana Biotechnology, Zhejiang University, Janssen Research & Development, Beijing Immunochina Medical Science & Technology, M.D. Anderson Cancer Center, SecuraBio, CARsgen Therapeutics, Caribou Biosciences, Atara Bio therapeutics, Wugen, Vor Biopharma, Juventas Cell Therapy, Hebei Senlang Biotechnology, Cellular Biomedicine Group, Oncternal Therapeutics, Autolus Limited, Lyell Immunopharma, Gracell Biopharmaceuticals and others.
  • Promising CAR T-Cell Therapy Therapies such as Itacitinib, Cyclophosphamide, Fludarabine, WU-CART-007, Cevostamab, JNJ-68284528, Lenalidomide, Daratumumab, KYV-101, Epcoritamab, and others.

Want to know which companies are leading innovation in CAR T-Cell Therapy? @ CAR T-Cell Therapy Clinical Trials Assessment

The CAR T-Cell Therapy Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The CAR T-Cell Therapy Pipeline Report also highlights the unmet needs with respect to the CAR T-Cell Therapy.

CAR T-Cell Therapy Overview

CAR-T cell therapy represents a revolutionary approach in cancer treatment, harnessing the power of the immune system to combat cancer. This cutting-edge therapy involves a meticulous process where a patient’s own T cells, a vital component of the immune system responsible for identifying and eliminating foreign invaders, are genetically engineered to specifically target and destroy cancer cells. The process begins by extracting T cells from the patient’s blood through a process called leukapheresis. Once isolated, these T cells undergo genetic modification in the laboratory. Specifically, scientists introduce a gene encoding a chimeric antigen receptor (CAR) into the T cells. This CAR is designed to recognize and bind to a specific protein expressed on the surface of cancer cells. This customization ensures that the engineered T cells can specifically target and attack cancerous cells while sparing healthy cells.

CAR T-Cell Therapy Emerging Drugs Profile

  • Descartes-08: Cartesian Therapeutics

Descartes-08 is an autologous anti-B cell maturation antigen (BCMA) mRNA CAR-T. Compared to conventional DNA-based CAR T-cell therapies, mRNA CAR-T is designed not to require preconditioning chemotherapy, has been observed to have predictable and controllable pharmacokinetics, and is designed to avoid the risk of genomic integration. Descartes-08 has been granted Orphan Drug Designation by the US FDA for the treatment of MG, a chronic autoimmune disorder that causes disabling muscle weakness and fatigue. Currently, the drug is in Phase II stage of clinical trial for the treatment of autoimmune disorders.

  • KYV-101: Kyverna Therapeutics

KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate for use in B cell-driven autoimmune diseases. The CAR in KYV-101 was designed by the National Institutes of Health (NIH) to improve tolerability and tested in a 20-patient Phase 1 trial in oncology. Results were published by the NIH in Nature Medicine3. KYV-101 is currently being evaluated in sponsored, open-label, Phase 1/2 trials of KYV-101 in patients with lupus nephritis, an autoimmune disease in which more than half of patients do not achieve a complete response to current therapies and are at risk of developing kidney failure. Additionally, FDA’s IND clearance has been obtained for Phase 2 trials of KYV-101 for multiple sclerosis and myasthenia gravis, and a Phase I/II trial for systemic sclerosis.

  • TX200: Sangamo Therapeutics

TX200 is composed of the patient’s own (autologous) regulatory T cells (Tregs) engineered to express a chimeric antigen receptor (CAR) designed to recognize the HLA-A2 protein present on a transplanted kidney and bind to it. TX200 is in development for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation from a living donor. It is in Phase I/II stage of its clinical trial.

  • ALLO-605: Allogene Therapeutics

ALLO-605, a next-generation AlloCAR T™ known as a TurboCAR™, is an investigational product that targets the B-cell maturation antigen (BCMA) for the treatment of patients with relapsed/refractory multiple myeloma and other BCMA-positive malignancies. This study uses ALLO-647, Allogene’s proprietary monoclonal antibody (mAb), as a part of its differentiated lymphodepletion regimen. ALLO-605 incorporates Allogene’s proprietary TurboCAR technology, which allows for cytokine activation signaling to be engineered selectively into CAR T cells. In June 2021, ALLO-605 was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of relapsed/refractory multiple myeloma. The Phase 1 study evaluating ALLO-605 is underway. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Multiple Myeloma.

  • ATA3219: Atara Biotherapeutics

ATA3219 combines the natural biology of unedited T cells with the benefits of an allogeneic therapy. It consists of allogeneic Epstein-Barr virus (EBV)-sensitized T cells that express a CD19 CAR construct for the treatment of CD19+ relapsed or refractory B-cell malignancies, including B-cell non-Hodgkin’s lymphoma and B-cell mediated autoimmune diseases including systemic lupus erythematosus (SLE) with kidney involvement (lupus nephritis [LN]). ATA3219 has been optimized to offer a potential best-in-class profile, featuring off-the-shelf availability. Currently, the drug is in Phase I stage of its clinical trial.

  • CB-010: Caribou Biosciences

CB-010 is an allogeneic anti-CD19 CAR-T cell therapy for the treatment of patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). CB-010 is the first allogeneic CAR-T cell therapy, to our knowledge, in a clinical trial with a PD-1 knockout, a genome-editing strategy designed to improve antitumor activity by limiting premature CAR-T cell exhaustion. CB-010 is being evaluated in the ongoing, open-label, multicenter ANTLER Phase I clinical trial in adults with r/r B-NHL.

If you’re tracking ongoing CAR T-Cell Therapy Clinical trials @ CAR T-Cell Therapy Treatment Drugs

The CAR T-Cell Therapy Pipeline report provides insights into:-

  • The report provides detailed insights about companies that are developing therapies for the treatment of CAR T-Cell Therapy with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for CAR T-Cell Therapy Treatment.
  • CAR T-Cell Therapy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • CAR T-Cell Therapy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the CAR T-Cell Therapy market.

CAR T-Cell Therapy Companies

Caribou Biosciences, Allogene Therapeutics, Synthekine, Shanghai Simnova Biotechnology, Sana Biotechnology, Zhejiang University, Janssen Research & Development, Beijing Immunochina Medical Science & Technology, M.D. Anderson Cancer Center, SecuraBio, CARsgen Therapeutics, Caribou Biosciences, Atara Bio therapeutics, Wugen, Vor Biopharma, Juventas Cell Therapy, Hebei Senlang Biotechnology, Cellular Biomedicine Group, Oncternal Therapeutics, Autolus Limited, Lyell Immunopharma, Gracell Biopharmaceuticals and others.

CAR T-Cell Therapy Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

CAR T-Cell Therapy Products have been categorized under various Molecule types such as,

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

From emerging drug candidates to competitive intelligence, the CAR T-Cell Therapy Pipeline Report @ CAR T-Cell Therapy Market Drivers and Barriers, and Future Perspectives

Scope of the CAR T-Cell Therapy Pipeline Report

  • Coverage- Global
  • CAR T-Cell Therapy Companies- Caribou Biosciences, Allogene Therapeutics, Synthekine, Shanghai Simnova Biotechnology, Sana Biotechnology, Zhejiang University, Janssen Research & Development, Beijing Immunochina Medical Science & Technology, M.D. Anderson Cancer Center, SecuraBio, CARsgen Therapeutics, Caribou Biosciences, Atara Bio therapeutics, Wugen, Vor Biopharma, Juventas Cell Therapy, Hebei Senlang Biotechnology, Cellular Biomedicine Group, Oncternal Therapeutics, Autolus Limited, Lyell Immunopharma, Gracell Biopharmaceuticals and others.
  • CAR T-Cell Therapy Therapies- Itacitinib, Cyclophosphamide, Fludarabine, WU-CART-007, Cevostamab, JNJ-68284528, Lenalidomide, Daratumumab, KYV-101, Epcoritamab, and others.
  • CAR T-Cell Therapy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • CAR T-Cell Therapy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the CAR T-Cell Therapy Treatment landscape in this detailed analysis @ CAR T-Cell Therapy Emerging Drugs and Major Players

Table of Contents

  1. Introduction
  2. Executive Summary
  3. CAR-T: Overview
  4. Pipeline Therapeutics
  5. Therapeutics Assessment
  6. CAR-T– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Mid Stage Products (Phase II)
  9. Descartes-08: Cartesian Therapeutics
  10. Early Stage Products (Phase I)
  11. ATA3219: Atara Biotherapeutics
  12. Preclinical and Discovery Stage Products
  13. Inactive Products
  14. CAR-T Key Companies
  15. CAR-T Key Products
  16. CAR-T- Unmet Needs
  17. CAR-T- Market Drivers and Barriers
  18. CAR-T- Future Perspectives and Conclusion
  19. CAR-T Analyst Views
  20. CAR-T Key Companies
  21. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/car-t-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: CAR-T Pipeline Expands as 180+ Companies Driving Innovation in the Therapeutics | DelveInsight